메뉴 건너뛰기
Infectious Diseases in Clinical Practice
Volumn 22, Issue 2, 2014, Pages 92-95
Patients with recalcitrant clostridium difficile-associated diarrhea treated successfully with fidaxomicin: A case series
Author keywords

CDI; Clostridium difficile; Diarrhea; Fidaxomicin; Recurrence; Vancomycin
Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; PROBIOTIC AGENT; VANCOMYCIN;
EID: 84896709083     PISSN: 10569103     EISSN: 15369943     Source Type: Journal    
DOI: 10.1097/IPC.0b013e31829ff59b     Document Type: Article
Times cited : (3)
References (16)
  • 1
    • 79952585695 scopus 로고    scopus 로고
    • Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals
    • Miller BA, Chen LF, Sexton DJ, et al. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol. 2011;32:387Y390.
    • (2011) Infect Control Hosp Epidemiol. , vol.32 , pp. 387-390
    • Miller, B.A.1    Chen, L.F.2    Sexton, D.J.3
  • 2
    • 34447542645 scopus 로고    scopus 로고
    • Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States
    • Ricciardi R, Rothenberger DA, Madoff RD, et al. Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg. 2007;142:624Y631.
    • (2007) Arch Surg. , vol.142 , pp. 624-631
    • Ricciardi, R.1    Rothenberger, D.A.2    Madoff, R.D.3
  • 3
    • 55249105923 scopus 로고    scopus 로고
    • Clostridium difficileVmore difficult than ever
    • Kelly CP, LaMont JT. Clostridium difficileVmore difficult than ever. N Engl J Med. 2008;359:1932Y1940.
    • (2008) N Engl J Med. , vol.359 , pp. 1932-1940
    • Kelly, C.P.1    Lamont, J.T.2
  • 4
    • 79551527297 scopus 로고    scopus 로고
    • Fidaxomicin versus vancomycin for Clostridium difficile infection
    • Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011; 364:422Y431.
    • (2011) N Engl J Med. , vol.364 , pp. 422-431
    • Louie, T.J.1    Miller, M.A.2    Mullane, K.M.3
  • 5
    • 77951026738 scopus 로고    scopus 로고
    • Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)
    • Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431Y455.
    • (2010) Infect Control Hosp Epidemiol. , vol.31 , pp. 431-455
    • Cohen, S.H.1    Gerding, D.N.2    Johnson, S.3
  • 6
    • 0036311186 scopus 로고    scopus 로고
    • Breaking the cycle: Treatment strategies for 163 cases of recurrent Clostridium difficile disease
    • McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol. 2002;97:1769Y1775.
    • (2002) Am J Gastroenterol. , vol.97 , pp. 1769-1775
    • McFarland, L.V.1    Elmer, G.W.2    Surawicz, C.M.3
  • 7
    • 62249153924 scopus 로고    scopus 로고
    • Recurrent Clostridium difficile infection: Causality and therapeutic approaches
    • Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents. 2009;33:S33YS36.
    • (2009) Int J Antimicrob Agents. , vol.33
    • Johnson, S.1
  • 8
    • 84859007390 scopus 로고    scopus 로고
    • Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: A double-blind, non-inferiority, randomised controlled trial
    • Cornely OA, Crook DW, Esposito R, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12:281Y289.
    • (2012) Lancet Infect Dis. , vol.12 , pp. 281-289
    • Cornely, O.A.1    Crook, D.W.2    Esposito, R.3
  • 9
    • 84863676557 scopus 로고    scopus 로고
    • Treatment of first recurrence of Clostridium difficile infection: Fidaxomicin versus vancomycin
    • Cornely OA, Miller MA, Louie TJ, et al. Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin. Clin Infect Dis. 2012;55:S154YS161.
    • (2012) Clin Infect Dis. , vol.55
    • Cornely, O.A.1    Miller, M.A.2    Louie, T.J.3
  • 10
    • 59749103290 scopus 로고    scopus 로고
    • OPT-80 eliminates clostridium difficile and is sparing of bacteroides species during treatment of C. Difficile infection
    • Louie TJ, Emery J, Krulicki W, et al. OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection. Antimicrob Agents Chemother. 2009;53:261Y263.
    • (2009) Antimicrob Agents Chemother. , vol.53 , pp. 261-263
    • Louie, T.J.1    Emery, J.2    Krulicki, W.3
  • 11
    • 84863710720 scopus 로고    scopus 로고
    • Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection
    • Sears P, Crook DW, Louie TJ, et al. Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection. Clin Infect Dis. 2012;55:S116YS120.
    • (2012) Clin Infect Dis. , vol.55
    • Sears, P.1    Crook, D.W.2    Louie, T.J.3
  • 12
    • 84893433896 scopus 로고    scopus 로고
    • Fidaxomicin inhibits production of toxin A and toxin B in Clostridium difficile [abstract]
    • Bouillaut L, Sims C, Gomez A, et al. Fidaxomicin inhibits production of toxin A and toxin B in Clostridium difficile [abstract]. J Hosp Med. 2012;7:S77.
    • (2012) J Hosp Med. , vol.7
    • Bouillaut, L.1    Sims, C.2    Gomez, A.3
  • 13
    • 84863641928 scopus 로고    scopus 로고
    • Fidaxomicin inhibits spore production in Clostridium difficile
    • Babakhani F, Bouillaut L, Gomez A, et al. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis. 2012;55:S162YS169.
    • (2012) Clin Infect Dis. , vol.55
    • Babakhani, F.1    Bouillaut, L.2    Gomez, A.3
  • 14
    • 80051957059 scopus 로고    scopus 로고
    • Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections
    • Mullane KM, Miller MA,Weiss K, et al. Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections. Clin Infect Dis. 2011;53:440Y447.
    • (2011) Clin Infect Dis. , vol.53 , pp. 440-447
    • Mullane, K.M.1    Miller Maweiss, K.2
  • 15
    • 84871740349 scopus 로고    scopus 로고
    • Fidaxomicin "Chaser" regimen following vancomycin for patients with multiple C. Difficile recurrences
    • Johnson S, Gerding DN. Fidaxomicin "Chaser" regimen following vancomycin for patients with multiple C. difficile recurrences. Clin Infect Dis. 2012;56:309Y310.
    • (2012) Clin Infect Dis. , vol.56 , pp. 309-310
    • Johnson, S.1    Gerding, D.N.2
  • 16
    • 84873019302 scopus 로고    scopus 로고
    • Duodenal infusion of donor feces for recurrent Clostridium difficile
    • van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407Y415.
    • (2013) N Engl J Med. , vol.368 , pp. 407-415
    • Van Nood, E.1    Vrieze, A.2    Nieuwdorp, M.3

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.